Drugs for Hereditary Spastic Paraplegia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 26)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Acetylcholine |
Approved, Investigational |
Phase 2, Phase 3 |
|
51-84-3 |
187
|
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
2 |
|
Cholinergic Agents |
|
Phase 2, Phase 3 |
|
|
|
3 |
|
Neurotransmitter Agents |
|
Phase 2, Phase 3 |
|
|
|
4 |
|
Acetylcholine Release Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
5 |
|
Botulinum Toxins |
|
Phase 2, Phase 3 |
|
|
|
6 |
|
Resveratrol |
Approved, Experimental, Investigational |
Phase 2 |
|
501-36-0 |
445154
|
Synonyms:
(e)-5-(2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol
(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol
(e)-Resveratrol
(E)-resveratrol
3,4',5-Stilbenetriol
3,4',5-trihydroxystilbene
3,4',5-Trihydroxystilbene
3,4',5-trihydroxy-trans-stilbene
3,4',5-Trihydroxy-trans-stilbene
3,5,4'-trihydroxystilbene
|
3,5,4'-Trihydroxystilbene
5-[(e)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol
5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol
cis-Resveratrol
Resveratrol-3-sulfate
SRT 501
SRT-501
trans-3,4',5 - Trihydroxystilbene
trans-resveratrol
trans-Resveratrol
|
|
7 |
|
chenodeoxycholic acid |
Approved |
Phase 2 |
|
474-25-9 |
10133
|
Synonyms:
(+)-Chenodeoxycholate
(+)-Chenodeoxycholic acid
(3a,5b,7a)-3,7-Dihydroxy-cholan-24-Oate
(3a,5b,7a)-3,7-Dihydroxy-cholan-24-Oic acid
3a,7a-Dihydroxy-5b,14a,17b-cholanate
3a,7a-Dihydroxy-5b,14a,17b-cholanic acid
3a,7a-Dihydroxy-5b-cholan-24-Oate
3a,7a-Dihydroxy-5b-cholan-24-Oic acid
3a,7a-Dihydroxy-5b-cholanate
3a,7a-Dihydroxy-5b-cholanic acid
3alpha,7alpha-Dihydroxy-5beta-cholanate
3alpha,7alpha-Dihydroxy-5beta-cholanic acid
3α,7α-dihydroxy-5β-cholanate
3α,7α-dihydroxy-5β-cholanic acid
7a-Hydroxy-desoxycholsaeure
7a-Hydroxylithocholate
7a-Hydroxylithocholic acid
7alpha-Hydroxylithocholate
7alpha-Hydroxylithocholic acid
7α-hydroxylithocholate
7α-hydroxylithocholic acid
Acid, chenic
Acid, chenique
Acid, chenodeoxycholic
Acid, gallodesoxycholic
Acide chenodeoxycholique
Acido chenodeoxicholico
Acidum chenodeoxycholicum
Anthropodeoxycholate
|
Anthropodeoxycholic acid
Anthropodesoxycholate
Anthropodesoxycholic acid
Antigen brand OF chenodeoxycholic acid
CDCA
Chenate
Chenic acid
Chenique acid
Chenix
Chenocholic acid
Chenodeoxycholate
Chenodeoxycholate, sodium
Chenodeoxycholic acid
Chenodesoxycholic acid
Chenodesoxycholsaeure
Chenodiol
Chenofalk
Chenophalk
Estedi brand OF chenodeoxycholic acid
Falk brand OF chenodeoxycholic acid
Gallodesoxycholate
Gallodesoxycholic acid
Henohol
Quenobilan
Quenocol
Sodium chenodeoxycholate
Solvay brand OF chenodeoxycholic acid
tramedico Brand OF chenodeoxycholic acid
Zambon brand OF chenodeoxycholic acid
|
|
8 |
|
Atorvastatin |
Approved |
Phase 2 |
|
134523-00-5 |
60823
|
Synonyms:
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-b,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoate
(R-(R*,r*))-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid
134523-00-5
134523-03-8
7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoate
7-[2-(4-fluoro-PHENYL)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoIC ACID
AC-15611
AC1L1TZT
AC1Q1OZQ
AKOS000281127
Anhydrous, atorvastatin calcium
Atogal
Atorlip
Atorpic
atorvastatin
Atorvastatin
Atorvastatin (INN)
Atorvastatin [INN:BAN]
Atorvastatin acid
Atorvastatin calcium
Atorvastatin calcium anhydrous
Atorvastatin calcium hydrate
Atorvastatin calcium trihydrate
Atorvastatin, calcium salt
atorvastatina
Atorvastatina
atorvastatine
Atorvastatine
atorvastatinium
atorvastatinum
Atorvastatinum
atrovastin
BIDD:GT0336
C06834
C33H35FN2O5
|
Calcium anhydrous, atorvastatin
Calcium hydrate, atorvastatin
Calcium salt atorvastatin
Calcium trihydrate, atorvastatin
Calcium, atorvastatin
Cardyl
CCRIS 7159
CHEBI:39548
CHEMBL1487
CI 981
CID60823
D07474
DB01076
Faboxim
Hipolixan
HSDB 7039
Hydrate, atorvastatin calcium
Lipitor
Lipitor (TN)
Lipitor(TM)
Lipotropic
Lipovastatinklonal
Liprimar
Liptonorm
Lowden
LS-136975
MolPort-000-883-773
NCGC00159458-02
nchembio.301-comp8
Normalip
Sincol
Sortis
Sortis (TN)
Sotis
Torvacard
Torvast
Totalip
Tozalip
Trihydrate, atorvastatin calcium
Tulip
UNII-A0JWA85V8F
Vastina
Xanator
Xarator
Xavator
Zurinel
|
|
9 |
|
Analgesics |
|
Phase 2 |
|
|
|
10 |
|
Antineoplastic Agents, Phytogenic |
|
Phase 2 |
|
|
|
11 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
12 |
|
Cathartics |
|
Phase 2 |
|
|
|
13 |
|
Lipid Regulating Agents |
|
Phase 2 |
|
|
|
14 |
|
Anti-Inflammatory Agents, Non-Steroidal |
|
Phase 2 |
|
|
|
15 |
|
Antioxidants |
|
Phase 2 |
|
|
|
16 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
17 |
|
Peripheral Nervous System Agents |
|
Phase 2 |
|
|
|
18 |
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors |
|
Phase 2 |
|
|
|
19 |
|
Protective Agents |
|
Phase 2 |
|
|
|
20 |
|
Laxatives |
|
Phase 2 |
|
|
|
21 |
|
Hypolipidemic Agents |
|
Phase 2 |
|
|
|
22 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
23 |
|
Platelet Aggregation Inhibitors |
|
Phase 2 |
|
|
|
24 |
|
Anticholesteremic Agents |
|
Phase 2 |
|
|
|
25 |
|
Antirheumatic Agents |
|
Phase 2 |
|
|
|
26 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 14)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study |
Completed |
NCT02604186
|
Phase 2, Phase 3 |
|
2 |
Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 |
Completed |
NCT02314208
|
Phase 2 |
Xenbilox;Tahor |
3 |
Design and Validation of a Modular Physiotherapy Concept for the Treatment of Hereditary Spastic Spinal Paralysis (HSP) - a Randomized Study |
Completed |
NCT03961906
|
Phase 2 |
|
4 |
A Pilot Study of Repetitive Transcranial Magnetic Stimulation for Improvement of Gait in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy |
Completed |
NCT03627416
|
|
|
5 |
Studying Cognition in SPG4 Compared to Healthy Controls |
Completed |
NCT03104088
|
|
|
6 |
Disease Natural History and Biomarkers of SPG3A, SPG4 and SPG31 |
Recruiting |
NCT02859428
|
|
|
7 |
Phenotype, Genotype & Biomarkers in ALS and Related Disorders |
Recruiting |
NCT02327845
|
|
|
8 |
Studying the Presymptomatic and Early Phase of SPG4 |
Recruiting |
NCT03206190
|
|
|
9 |
Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of Childhood |
Recruiting |
NCT01568658
|
|
|
10 |
Studying Non-motor Symptoms in Patients With Hereditary Spastic Paraplegia (HSP) Compared to Healthy Controls |
Recruiting |
NCT03204773
|
|
|
11 |
Coordination of Rare Diseases at Sanford |
Recruiting |
NCT01793168
|
|
|
12 |
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale |
Enrolling by invitation |
NCT02852278
|
|
|
13 |
Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders |
Not yet recruiting |
NCT03981276
|
|
|
14 |
Investigating the Role of SPG20,STK31 Genes in the Carcinogenesis of Colorectal Cancer |
Not yet recruiting |
NCT03261752
|
|
|
|